ScreenerHero

MESO Mesoblast Limited

NAS · US · Healthcare · Biotechnology · mesoblast.com
13.94USD+2.42%Mkt Cap: 1.81B $P/E: —

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized ce…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.81B USD
Enterprise Value1.79B USD
Revenue (TTM)120.25M USD
Gross Profit103.58M USD
Net Income (TTM)-57.50M USD
Revenue/Share0.93 USD
Last Price13.94 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees108
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)29.91
PEG—
EV/EBITDA-40.24
EV/Revenue14.93
P/S14.70
P/B3.11
EPS (TTM)-0.44
EPS (Forward)0.46
52W Range
13.0511% of range21.50
52W High21.50 USD
52W Low13.05 USD
Profitability
Gross Margin86.14%
Oper. Margin-33.28%
EBITDA Margin-37.09%
Profit Margin-47.82%
ROE-10.12%
ROA-7.44%
Growth
Revenue Growth390.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-43.83M USD
CapEx (TTM)898.00K USD
FCF Margin-43.22%
FCF Yield-2.87%
Net Debt24.42M USD
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity0.22
Current Ratio2.44
Quick Ratio1.98
Book Value/Sh4.38 USD
Cash/Share0.79 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:2
Split DateJan 10, 2024
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)37.00 USD
Upside (mean)+165.4%
Target Range35.00 USD – 39.00 USD
35.00+165.4% to mean39.00
# Analysts2
Ownership
Shares Out.129.85M
Float86.11M
Insiders57.38%
Institutions3.27%
Short Interest
Short Ratio16.1d
Short % Float3.49%
Short % Out.2.55%
Shares Short3.31M
Short (prev mo.)3.01M
Technical
SMA 5015.77 (-11.6%)
SMA 20015.92 (-12.5%)
Beta0.86
S&P 52W Chg15.78%
Avg Vol (30d)202.41K
Avg Vol (10d)238.91K
Technical Indicators
RSI (14)39.0
MACD-0.5614
MACD Signal-0.4221
MACD Hist.-0.1393
BB Upper16.49 USD
BB Middle14.98 USD
BB Lower13.47 USD
BB Width20.17%
ATR (14)0.5446 USD
Vol Ratio (20d)0.90x